Reimbursed Care Access in Morocco

Currently classified as a strictly controlled psychotropic/hallucinogenic substance under Moroccan drug control law and related decrees; there is no authorised medical psilocybin program or reimbursement pathway outside of approved clinical research. This classification follows the national schedules and government lists that group psilocybin/psilocin with hallucinogens prohibited for general use. # #

Currently classified as a strictly controlled substance (listed among hallucinogens/psychotropic substances in Moroccan scheduling instruments) with no authorised medical MDMA-assisted therapy program and no public reimbursement; access is limited to approved clinical research if and when specific research approvals are granted. # #

There is no public record of a national regulatory approval or reimbursement pathway for esketamine (Spravato) as a marketed, reimbursed antidepressant in Morocco; esketamine would therefore not be available through routine public insurance reimbursement and could only be accessed via authorised clinical trials or compassionate/individual import procedures where permitted by Moroccan authorities. Ketamine (the racemate) is used clinically in Moroccan hospitals as an anaesthetic and in acute/anaesthesia settings, but that established medical use does not imply national marketing authorisation or reimbursement for an esketamine nasal-spray product. For ketamine hospital use see clinical practice and hospital reviews from Moroccan centres. # # #

Ketamine (racemic ketamine) is an established anesthetic and analgesic used in Moroccan hospitals and emergency/anaesthesia practice; it is part of routine hospital formularies for induction, procedural sedation and for certain refractory status epilepticus or intensive‑care indications, and therefore is available in medical settings (public and private hospitals) though not as a reimbursed psychedelic therapy product. Clinical literature and hospital audits from Morocco document ketamine’s availability and clinical use in operating rooms, paediatric burn care, and refractory status epilepticus management in tertiary centres. # #

Regulatory/coverage context: Moroccan narcotics/psychotropic control law regulates distribution and prescription of controlled substances; ketamine is therefore dispensed and used under clinician prescription and institutional pharmacy controls, not via a specific reimbursed psychedelic‑therapy benefit. There is no published national reimbursement pathway for ketamine when used as an off‑label psychiatric intervention (e.g., for treatment‑resistant depression) and such use would generally be provided at institutional/private clinician discretion without a structured public reimbursement programme. #

Regional/state nuance: Morocco’s health system centralises drug regulation at national level; there are no subnational reimbursement programmes analogous to state‑level coverage seen in some federal countries — access/practice differences largely reflect hospital formularies (public vs private) and clinician practice rather than separate regional reimbursement policies.

Currently classified as a strictly controlled psychotropic/hallucinogenic substance under Moroccan drug law with no authorised medical use or reimbursement; access is limited to approved clinical research only (if authorised). # #

Currently classified as a strictly controlled psychotropic/hallucinogenic substance under national scheduling; there is no authorised medical program or reimbursement for 5‑MeO‑DMT in Morocco, and use/possession remains criminalised except within authorised research. # #

Currently classified as a strictly controlled substance under Moroccan drug control frameworks with no authorised medical use or reimbursement pathway; access would be limited to approved clinical research only. Morocco’s narcotics laws criminalise possession and unauthorised supply of psychotropic/hallucinogenic substances. # #

The primary active constituents of ayahuasca (DMT and MAO‑inhibiting plant compounds) fall under the controlled psychotropic drug framework; there is no legal, reimbursed medical pathway for ayahuasca ceremonies or therapeutic use in Morocco, and possession or preparation would be treated under general prohibitions on controlled psychotropic substances except where an authorised clinical research protocol is in place. # #

Listed among hallucinogens/psychotropic substances subject to strict control in Moroccan schedules (mescaline and peyote-type cacti are prohibited); there is no authorised medical mescaline program or public reimbursement and possession/supply is criminalised outside approved research. # #

The 2C family and related synthetic psychedelic compounds are expressly listed among controlled hallucinogens in Moroccan scheduling instruments and are illegal for non‑authorised purposes; there is no authorised medical use or reimbursement pathway and access is limited to approved clinical research only. # #